SCHEMBL4834658

SCHEMBL4834658

COc1ccc(S(=O)(=O)Nc2ccc(-c3nc4ncc(Cl)c(Cl)c4[nH]3)cc2)cc1

nearest known ligand 0.52

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
JAK1 P23458 7/20 0.52
AURKA O14965 1/20 0.51
SMN1; SMN2 Q16637 2/20 0.50
CHEK2 O96017 1/20 0.50
MAPT P10636 1/20 0.50
SGK1 O00141 1/20 0.49
JAK2 O60674 5/20 0.48
JAK3 P52333 3/20 0.48
SYK P43405 1/20 0.48
TBK1 Q9UHD2 2/20 0.47
PLAU P00749 1/20 0.47
KIT P10721 2/20 0.47
HPGD P15428 1/20 0.47
LMNA P02545 2/20 0.46
GAA P10253 1/20 0.46
MAPK1 P28482 1/20 0.46
TSHR P16473 1/20 0.46
HTT P42858 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22223723 0.85 SMN1; SMN2 (0.51) SMN1; SMN2CHEK2MAPTSGK1PLAU
SCHEMBL4833765 0.83 TBK1 (0.57) JAK1SMN1; SMN2CHEK2MAPTJAK2
SCHEMBL4843803 0.81 TP53 (0.46) JAK1SMN1; SMN2MAPTSGK1JAK2
SCHEMBL24325703 0.77 KIT (0.57) SMN1; SMN2MAPTPLAUKITHPGD
SCHEMBL6247592 0.75 TBK1 (0.47) JAK1SMN1; SMN2CHEK2MAPTJAK2
SCHEMBL3915297 0.72 MAPT (0.77) SMN1; SMN2CHEK2MAPTPLAUHPGD
SCHEMBL32679643 0.72 GAA (0.78) SMN1; SMN2MAPTPLAULMNAGAA
SCHEMBL790294 0.71 GAA (0.86) SMN1; SMN2MAPTPLAULMNAGAA
SCHEMBL789993 0.70 PPIA (0.79) SMN1; SMN2MAPTLMNAGAAMAPK1
SCHEMBL8752481 0.70 PPIA (0.79) SMN1; SMN2MAPTLMNAGAAMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7410966-B2 Use of and some novel imidazopyridines ASTRAZENECA AB (SE) 2008-08-12 US claimed
EP-1539759-B1 NOVEL IMIDAZOPYRIDINES AND THEIR USE ASTRAZENECA AB (SE) 2007-08-15 EP claimed
US-20050261333-A1 Use of and some novel imidazopyridines ASTRAZENECA A B (SE) 2005-11-24 US claimed
US-7410966-B2 Use of and some novel imidazopyridines ASTRAZENECA AB (SE) 2008-08-12 US disclosed
EP-1539759-B1 NOVEL IMIDAZOPYRIDINES AND THEIR USE ASTRAZENECA AB (SE) 2007-08-15 EP disclosed
US-20050261333-A1 Use of and some novel imidazopyridines ASTRAZENECA A B (SE) 2005-11-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050261333-A1 Use of and some novel imidazopyridines ITK, CSNK1A1, RPS6KA1 JAK1 291/4885AURKA 512/4885SMN1; SMN2 1377/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.